Skip to NavigationSkip to content

FDA approves first adjuvanted quadrivalent flu vaccine in over-65s

Published on 24/02/20 at 03:02pm

The FDA has just authorised its first adjuvanted quadrivalent influenza vaccine, it has been announced. Seqirus’ Fluad Quadrivalent (influenza vaccine, adjuvanted) has been approved in the US to for the prevention of seasonal vaccine in patients over the age of 65.

The new indication is crucial in seasonal flu; during the US influenza season of 2017/2018, 70% of flu-related hospitalisations occurred in over-65-year-olds, while 90% of flu-related deaths also occurred within this group.

Elderly patients can also experience impaired vaccine efficacy due to age-related decline of the immune system. The Centers for Disease Control and Prevention advise that all patients at least six months old receive an influenza vaccine shot on an annual basis.

This quadrivalent vaccine contains the same MF59 adjuvant technology as its Seqirus’ Fluad vaccine, and also covers an additional strain of influenza.  

"Adults 65 years and older are at high risk for influenza-related complications each season and it is important to have influenza vaccines to help protect this vulnerable population," commented Anjana Narain, Executive Vice President and General Manager at Seqirus. "As part of our leading role on the front line of influenza prevention, we are pleased to offer Fluad Quadrivalent as another seasonal vaccine option for healthcare providers and their patients in the fight against influenza."

Matt Fellows


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches